INTRODUCTION: Primary hyperoxaluria (PH) is a devastating disease in children and adults. Recently, a substantial progress in the treatment of this deadly disease has been made that consists of the introduction of the RNA inhibitors, lumasiran and nedosiran, which deplete the substrate for oxalate synthesis. METHODS: Lanthanum carbonate (Lanth.Carb., La RESULTS: Four patients with PH and estimated glomerular filtration rate >
60 ml/min per 1.73 m CONCLUSION: trcLanth.Carb. is a promising repurposed, efficient, nontoxic, and cheap drug, lacking serious side effects in the treatment of any type of PH in whatever place in the world. A randomized controlled trial supporting this proof-of-concept is the next step.